In GVHD models, ATRA promotes CD4+ Tregs generation to effectively alleviate GVHD but is unfavorable for CD8+ Tregs (78), which in turn indicates a differential response to ATRA by CD4+ and CD8+ Tregs and suggesting this possibility in vivo. The gene discussed is CD8A; the disease is graft versus host disease.